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The treatment of patients with congenital leukemia is diﬃcult and often results in a poor prognosis.  
We present here the case of a female child with congenital acute myeloid leukemia (AML) with t(8 ; 16)
(p11 ; p13) who received chemotherapy and survived for more than 10 years without relapse.  A novel 
MOZ︲CBP chimera was found in her diagnostic sample.  Although adult AML patients with MOZ︲CBP 
have mainly been reported as having therapy-related AML and showed poor prognoses,  the present 
case supports the idea that AML with MOZ︲CBP in the pediatric population might show better progno-
ses.
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C ongenital leukemia has been described as diﬃ-cult to treat and as showing very poor progno-
ses.  Bresters et al.  reviewed clinical data of patients 
with congenital leukemia reported in the literature 
from 1975 to 2000 and deﬁned the clinical character-
istics of 73 patients with congenital acute myeloid 
leukemia (AML): 63.3  showed complete remission 
and a 24.4  probability of overall survival at 24 
months of follow-up ﹇1﹈.  Ishii et al.  reported the 
features and outcomes of 11 neonatal leukemia 
patients in Japan including 3 neonatal AML patients:  
2 of the neonatal AML patients died within 1 month of 
birth and the third patient had been alive for＞7 years 
in complete remission as of the time of that report 
﹇2﹈.  Congenital leukemia seems to start in utero,  and 
thus a portion of intrauterine fetal deaths might be 
explained by congenital leukemia.
　 Congenital AML is more frequent compared to 
congenital acute lymphoid leukemia (ALL).  Some 
congenital AML patients who had t(8 ; 16)(p11 ; p13) 
showed relatively better prognoses compared to other 
congenital AML patients ﹇3﹈.  The reciprocal chromo-
somal rearrangement t(8 ; 16)(p11 ; p13) is character-
ized by disruption and fusion of MYST3╱MOZ on 
chromosome region 8p11 to CBP╱CREBBP on 16p13,  
which encodes a histone acetyltransferase and a tran-
scriptional co-activator/acetyltransferase,  respectively 
﹇4,  5﹈.  This rearrangement generates a MOZ︲CBP 
fusion protein,  and it inhibits AML1︲mediated tran-
scription,  resulting in a diﬀerentiation block.  Although 
the pathogenic pathway of AML with t(8 ; 16)(p11 ; p13) 
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is mostly unclear,  MOZ︲CBP fusion transcripts could 
play a role―such as leading to disruption in the bal-
ance between proliferation and diﬀerentiation during 
hematopoiesis ﹇6﹈.
　 We present here the case of a female patient with 
congenital AML with t(8 ; 16)(p11 ; p13) who survived 
for more than 10 years without relapse.  We found a 
novel transcript of MOZ︲CBP fusion in this case.  We 
also discuss the type of MOZ︲CBP fusion transcripts 
and its prognosis.
Materials and Methods
　 Patient. The patient was born at gestational 
age 37 weeks and 6 days by caesarian section due to 
maternal severe toxemia of pregnancy (birth weight 
1,988 g).  Multiple skin nodules were observed (Fig.  
1A),  and a skin biopsy suggested myeloid sarcoma.  A 
bone marrow smear showed increased CD13︲ and 
CD33︲positive monoblasts by ﬂow cytometry (Fig.  
1B).  A karyotype analysis showed 46,  XX,  t(8 ; 16)
(p11 ; p13) ﹇7/20﹈ (Fig.  1C).  MLL-rearrangement was 
not observed by a ﬂuorescence in situ hybridization 
(FISH) analysis.  She was diagnosed with AML FAB 
M5b,  and AML-oriented induction chemotherapy,  
etoposide,  cytarabine and mitoxantrone (ECM),  was 
started in accord with the AML99 study ﹇7﹈.  
Complete remission was achieved and followed by ﬁve 
consecutive cycles of consolidation chemotherapy with 
dose reduction,  due to adverse eﬀects.  After dis-
charge from the hospital,  she was healthy for more 
than 10 years without relapse or the development of a 
short stature.  Informed consent was obtained from the 
patient and her parents.
　 Sequencing analysis. Total RNA was extracted 
from the patientʼs ﬁrst diagnostic bone marrow sample 
using the QIAGEN RNeasy Mini Kit (QIAGEN,  
Hilden,  Germany),  and 1︲2 ng total RNA was 
reverse-transcribed to cDNA using the RETROscript 
Kit (Ambion,  Austin,  TX,  USA) according to the 
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Fig. 1　 (A) Multiple skin nodules were found on the patient’s back and superior limb.  Spontaneous regression was observed after che-
motherapy.  (B) Pictures of blasts in her bone marrow smear.  May-Giemsa staining×100 showed the increase in monoblasts in the bone 
marrow smear.  (C) Karyotype by the G-banding method showed t (8 ; 16)(p11 ; p13) in this patient.
manufacturerʼs instructions.  Reverse transcriptase-
polymerase chain reaction (RT-PCR) was carried out 
using the AmpliTaq Gold 360 Master Mix (Applied 
Biosystems,  Foster City,  CA,  USA) according to the 
manufacturerʼs instructions except for the use of 
1.3µg cDNA.  The primers for RT-PCR were 
MOZ4024F (5ʼ︲GTTGAGCCAAAAGAAGACATG 
CC︲3ʼ),  a new primer,  and CBP1201R (5ʼ︲GTTGC 
AATTGCTTGTGTGGGTAC︲3ʼ).  PCR-amplified 
fragments were puriﬁed using the QIAquick PCR 
Puriﬁcation Kit (QIAGEN) according to the manufac-
turerʼs instructions.  DNA sequencing of the PCR-
ampliﬁed fragments was performed using the Big Dye 
terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems),  the illustra AutoSeq G︲50 Dye 
Terminator Removal Kit (GE Healthcare UK,  
Buckinghamshire,  UK),  Hi-Di Formamide (Applied 
Biosystems),  and a 3130xl Genetic Analyzer (Applied 
Biosystems) according to the manufacturerʼs instruc-
tions.  The sequencing analysis and alignment were 
performed using BLAST software (http://blast.ncbi.
nlm.nih.gov/Blast.cgi).
Results
　 The results of the sequence analysis showed that 
base pair (bp) 4,198 of MOZ exon 17 (accession num-
ber U47742.1) was fused to bp 1,007 of CBP exon 3 
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Fig. 2　 (A) Partial sequence chromatogram showing the junction of MOZ and CBP genes (arrows).  MOZ︲CBP fusion transcript was 
detected in the patient’s ﬁrst diagnostic bone marrow sample.  (B) Types and frequency of MOZ︲CBP fusion transcripts.
(acc. no. NM_004380.2) (Fig.  2A).  At this junction,  
there was a 6︲bp stretch of an unknown fragment,  
which may correspond to base pairs 4,199︲4,204 of 
MOZ exon 17 or base pairs 4,199︲4,200 of MOZ exon 
17,  which were fused to base pairs 1,003︲1,006 of 
CBP exon 3.
Discussion
　 The reciprocal chromosomal rearrangement t(8 ; 16)
(p11 ; p13) is rare in both adult and pediatric AML 
patients,  accounting for 0.2︲0.4  of de novo AML 
cases.  Several studies reported that pediatric AML 
cases with t(8 ; 16)(p11 ; p13) are a distinct clinical 
and biological entity.  For example,  Coenen et al.  
reported a cohort study of 62 pediatric AML cases 
with t(8 ; 16)(p11 ; p13); they observed that AML 
cases with t(8 ; 16)(p11 ; p13) had M4 or M5 (97 ),  
erythrophagocytosis (70 ),  leukemia cutis (58 ),  
and disseminated intravascular coagulation (39 ),  and 
they also reported that the AML cases with t(8 ; 16)
(p11 ; p13) had a higher frequency of congenital cases 
compared to other AML cases ﹇8﹈.  Diaz-Beya et al.  
reported that AML cases with t(8 ; 16)(p11 ; p13) had 
a distinct signature characterized mainly by the down-
regulation of multiple microRNAs,  some of which are 
responsible for the high RET proto-oncogene levels 
﹇9﹈.  Camos et al.  reported the distinctive gene 
expression proﬁle of MOZ︲CBP AML,  with overex-
pression of RET and prolactin (PRL) and a speciﬁc 
pattern of homeobox (HOX) gene expression ﹇10﹈.
　 The majority of adult AML cases with t(8 ; 16)
(p11 ; p13) are secondary to therapy and poor progno-
sis ﹇11,  12﹈.  The pediatric AML cases with t(8 ; 16)
(p11 ; p13) showed relatively good prognosis in recent 
reports.  Daifu et al.  reported that congenital AML 
cases with MOZ︲CBP treated only with induction 
chemotherapy showed long-term remission ﹇3﹈.  Terui 
K.  et al.  reported that an infant AML case with MOZ︲
CBP spontaneously resulted in complete remission 
﹇13﹈.  Wu et al.  reported a congenital AML case with 
t(8 ; 16)(p11 ; p13) who spontaneously resulted in 
complete remission ﹇14﹈.
　 To date,  7 types of MOZ︲CBP fusion transcripts 
have been identiﬁed (Fig.  2B).  Type I is the most 
common transcript found in adults with poor prognosis,  
and types VI and VII have been detected only in the 
pediatric population ﹇13﹈.  The diﬀerence in the prog-
nosis of AML cases with t(8 ; 16)(p11 ; p13) between 
the adult and pediatric populations might be a result 
of the diﬀerence in the type of MOZ︲CBP fusion tran-
scripts.
　 The present case supports the idea that pediatric 
AML cases with MOZ︲CBP which is a rare type of 
MOZ︲CBP and not type I show a relatively good prog-
nosis.  More AML t(8 ; 16)(p11 ; p13) cases,  both 
pediatric and adult,  must be analyzed to clarify the 
clinical utility of the types of MOZ︲CBP fusion tran-
scripts.
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